Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030641 | 0.92 | NPC1 (0.47) | NPC1RAB9AHTTPOLBGSK3B | |
| SCHEMBL27758566 | 0.82 | NPC1 (0.53) | NPC1RAB9AHTTPOLBGSK3B | |
| SCHEMBL2030204 | 0.72 | KDM4E (0.48) | NPC1RAB9AHTTPOLBAKR1C3 | |
| SCHEMBL2032051 | 0.72 | MCL1 (0.61) | NPC1RAB9AHTTPOLBAKR1C3 | |
| SCHEMBL4272417 | 0.71 | TDP1 (0.59) | NPC1RAB9AHTTPOLBMEN1 | |
| SCHEMBL27779567 | 0.70 | NPC1 (0.40) | NPC1RAB9AHTTPOLBPIK3CD | |
| SCHEMBL17532996 | 0.68 | NTRK1 (0.47) | KDR | |
| SCHEMBL18610120 | 0.68 | HDAC1 (0.48) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL12079338 | 0.68 | MAPK14 (0.51) | AKR1C3AKR1C2IRAK4KDR | |
| SCHEMBL18609687 | 0.67 | KMT2A (0.63) | POLBMEN1MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073811-B1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8586565-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013036232-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| US-7790756-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2073811-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046003-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | ABL1, MCL1, ABL2 | NPC1 3601/4885RAB9A 1325/4885HTT 3116/4885 |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | MYLK3, MYLK, CDK3 | NPC1 3414/4885RAB9A 1929/4885HTT 4634/4885 |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | MYLK3, MYLK, CDK3 | NPC1 3414/4885RAB9A 1929/4885HTT 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.